Vancomycin therapy of severe staphylococcal infections

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• The increasing incidence of methicillin-resistant staphylococci necessitates effective treatment options.
• Vancomycin has been clinically available for approximately 30 years.
• Widespread use of vancomycin has occurred over the past decade.

Purpose of the Study:

• To summarize recent literature on the efficacy of vancomycin.
• To highlight vancomycin's role in treating resistant staphylococcal infections.

Main Methods:

• Review of recent articles on vancomycin efficacy.
• Synthesis of data on vancomycin's properties and clinical use.

Main Results:

• Vancomycin exhibits bactericidal action.
• It achieves high and prolonged blood levels.
• No resistant strains have emerged.
• Purified preparations show decreased adverse reactions.
• Vancomycin is an excellent agent for staphylococcal infections resistant to beta-lactam antibiotics.

Conclusions:

• Vancomycin remains a crucial antibiotic for specific staphylococcal infections.
• Its favorable characteristics support its continued use.
• Further review of its efficacy confirms its clinical value.